These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 7828457)

  • 41. [PK/PD modeling of aminoglycoside nephrotoxicity].
    Rougier F; Corvaisier S; Ducher M; Claude D; Jelliffe RW; Maire P
    Pathol Biol (Paris); 2003 Jun; 51(4):234-6. PubMed ID: 12853000
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections.
    Giamarellou H; Yiallouros K; Petrikkos G; Moschovakis E; Vavouraki E; Voutsinas D; Sfikakis P
    J Antimicrob Chemother; 1991 May; 27 Suppl C():73-9. PubMed ID: 1906864
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Amikacin and kanamycin. Comparative experimental studies on nephrotoxicity].
    Züllich B; Sack K
    Arzneimittelforschung; 1978; 28(2):271-8. PubMed ID: 580391
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Age-dependent enzymuria, proteinuria and changes in renal blood flow and glomerular filtration rate in rats.
    Casadevall G; Piera C; Setoain J; Queralt J
    Mech Ageing Dev; 1995 Jul; 82(1):51-60. PubMed ID: 7475356
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A controlled study of the nephrotoxicity of mezlocillin and amikacin in the neonate.
    Adelman RD; Wirth F; Rubio T
    Am J Dis Child; 1987 Nov; 141(11):1175-8. PubMed ID: 3314475
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of 'high-dose' amikacin in children.
    Kumor KM; McDonald JM; Lietman PS
    Dev Pharmacol Ther; 1984; 7(6):368-76. PubMed ID: 6518944
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients.
    Vic P; Ategbo S; Turck D; Husson MO; Tassin E; Loeuille GA; Deschildre A; Druon D; Elian JC; Arrouet-Lagandre C; Farriaux JP
    Eur J Pediatr; 1996 Nov; 155(11):948-53. PubMed ID: 8911895
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ototoxicity and nephrotoxicity of amikacin: an overview of phase II and phase III experience in the United States.
    Lane AZ; Wright GE; Blair DC
    Am J Med; 1977 Jun; 62(6):911-8. PubMed ID: 868905
    [No Abstract]   [Full Text] [Related]  

  • 49. Gentamicin in neonatal infection: once versus twice daily dosage.
    Chotigeat U; Narongsanti A; Ayudhya DP
    J Med Assoc Thai; 2001 Aug; 84(8):1109-15. PubMed ID: 11758844
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [In the search for effective and safe dose of amikacin in patients with chronic kidney disease].
    Gomółka M; Szamotulska K; Rymarz A; Brodowska-Kania D; Dubchak I; Piechota W; Jurkiewicz D; Niemczyk S
    Pol Merkur Lekarski; 2014 Apr; 36(214):240-4. PubMed ID: 24868895
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
    Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
    Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acute effects of acetaminophen on renal function and urinary excretion of some proteins and enzymes in patients with kidney disease.
    Mitić-Zlatković M; Stefanović V
    Ren Fail; 1999 Sep; 21(5):525-32. PubMed ID: 10516997
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Pharmacokinetics and toxicity of gentamycin in the newborn infant].
    Aujard Y
    Pediatrie; 1986 Mar; 41(2):165-8. PubMed ID: 3774428
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protective effect of creatine on amikacin-induced ototoxicity.
    Apaydın E; Dağlı E; Bayrak S; Kankılıç ES; Şahin H; Acar A
    Braz J Otorhinolaryngol; 2022; 88(5):651-656. PubMed ID: 33121925
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enzymuria in non-insulin-dependent diabetic patients: signs of tubular cell dysfunction.
    Ikenaga H; Suzuki H; Ishii N; Itoh H; Saruta T
    Clin Sci (Lond); 1993 Apr; 84(4):469-75. PubMed ID: 8097685
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Excretion of N-acetyl-beta-D-glucosaminidase in the urine of children with type I juvenile diabetes mellitus and of patients treated with the aminoglycoside amikacin].
    Wiesmann U; Peheim E; Colombo JP
    Klin Wochenschr; 1989; 67 Suppl 17():40-3. PubMed ID: 2739356
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Renal drug clearance in preterm neonates: relation to prenatal growth.
    Allegaert K; Anderson BJ; van den Anker JN; Vanhaesebrouck S; de Zegher F
    Ther Drug Monit; 2007 Jun; 29(3):284-91. PubMed ID: 17529884
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tobramycin and amikacin nephrotoxicity. Value of serum creatinine versus urinary concentration of beta-2-microglobulin.
    Gatell JM; SanMiguel JG; Zamora L; Araujo V; Castells C; Moreno A; Jimenez de Anta MT; Marin JL; Elena M; Ballesta A
    Nephron; 1985; 41(4):337-43. PubMed ID: 3906418
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin.
    Hermida J; Tutor JC
    Ther Drug Monit; 2006 Jun; 28(3):326-31. PubMed ID: 16778715
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of haemodialysis as a protective technique for preventing high daily dose amikacin nephrotoxicity: an experimental study in an ovine model.
    Pouzot-Nevoret C; Magnin M; Ayoub JY; Bourguignon L; Maire P; Wertz D; Goy-Thollot I; Barthélemy A; Boselli E; Allaouchiche B; Bonnet-Garin JM
    Int J Antimicrob Agents; 2017 Aug; 50(2):148-154. PubMed ID: 28689868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.